HomeAI · summaries
Storia in 6 fonti
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
FDA Staff Unconvinced Drug for Melanoma Shows Benefit
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
- ·
statnews.com
FDA staff reiterate concerns about Replimune skin cancer treatment
Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.
